Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump
Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and investment returns in 2024.Read more...
Wegovy sales took a hit this year. Novo's CEO blames off-brand competi
<img class="type:primaryImage" src="https://i.kinja-img.com/image/upload/c_fit,q_80,w_636/80d83acceff64c4fc5851e3ab8f802f1.jpg"/><p>Sales of Novo Nordisk’s (<a cla [...]